Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01801709
Other study ID # C11-09
Secondary ID 2011-004410-42
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 2014
Est. completion date May 2029

Study information

Verified date January 2022
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this open-label, single arm, monocentric, phase I/II clinical study is to assess safety and efficacy of ARSA gene transfer in the brain of children affected with early onset forms of Metachromatic Leukodystrophy (MLD). For this purpose, an adeno-associated virus serotype rh.10 (AAVrh.10) vector will be used to transfer the ARSA cDNA coding for Arylsulfatase A (ARSA) enzyme into the brain of children. Five patients with early onset form of MLD, age ranging from 6 months to 4 years, will be included in this protocol and will be followed during 24 months. Patients will be selected at presymptomatic or early stage of their disease, following clinical, neuropsychological and brain imaging criteria. Twelve simultaneous injections of the investigational medicinal product will be performed in the white matter of both brain hemispheres, through 6 image-guided tracks, with 2 deposits per track. A low dose (1x10EXP12 vg total) will be administered to the first 2 patients, while the last 3 will receive a higher dose (4x10EXP12 vg total). Safety and efficiency will be evaluated based on clinical, neuropsychological, radiological, electrophysiological and biological parameters.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 5
Est. completion date May 2029
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 6 Months to 5 Years
Eligibility Inclusion Criteria: - Boys or girls with an early onset form of MLD. - Age between 6 months and 5 years, inclusive - Diagnostic of MLD based on the measurement of ARSA activity in leukocytes and the accumulation of sulfatides in urine, along with normal activity of at least one other sulfatase - Informed consent signed up and willingness for monitoring 2 years after treatment. - Normal values for standard laboratory tests Exclusion Criteria: - Absence of ARSA protein by immunocytochemistry and/or ELISA - Gestational age <32 weeks of amenorrhoea and age < 1 year - Brain atrophy with a subdural space > 10 mm in the frontal region - Performance IQ<50 at WPPSI-III or cognitive function < 3rd percentile at the Bayley's test of infant development - If age > 16 months at inclusion, inability to walk few steps alone OR inability to walk few steps with support on one side along with inability to stand up alone - Impossibility for anesthesia - Malignancy, cardiac malformation, liver dysfunction, or renal dysfunction - Neurological disorder, except benign, not related to MLD. - Any other clinically significant untreated co-morbid medical condition as determined by the clinical investigator, including cardiac, pulmonary or kidney disease. - MRI impossibility - Evoked potential impossibility - Participation to another therapeutic clinical trial for MLD. - Unaffiliated to any French or any other National Health Insurance.

Study Design


Intervention

Genetic:
intracerebral administration of AAVrh.10cuARSA


Locations

Country Name City State
France Bicêtre Hospital - Paris Sud Le Kremlin-Bicêtre

Sponsors (3)

Lead Sponsor Collaborator
Institut National de la Santé Et de la Recherche Médicale, France Assistance Publique - Hôpitaux de Paris, European Leukodystrophy Association

Country where clinical trial is conducted

France, 

References & Publications (4)

Colle MA, Piguet F, Bertrand L, Raoul S, Bieche I, Dubreil L, Sloothaak D, Bouquet C, Moullier P, Aubourg P, Cherel Y, Cartier N, Sevin C. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet. 2010 Jan 1;19(1):147-58. doi: 10.1093/hmg/ddp475. — View Citation

i Dali C, Hanson LG, Barton NW, Fogh J, Nair N, Lund AM. Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology. 2010 Nov 23;75(21):1896-903. doi: 10.1212/WNL.0b013e3181feb217. — View Citation

Piguet F, Sondhi D, Piraud M, Fouquet F, Hackett NR, Ahouansou O, Vanier MT, Bieche I, Aubourg P, Crystal RG, Cartier N, Sevin C. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum Gene Ther. 2012 Aug;23(8):903-14. doi: 10.1089/hum.2012.015. Epub 2012 Jul 23. — View Citation

Sondhi D, Johnson L, Purpura K, Monette S, Souweidane MM, Kaplitt MG, Kosofsky B, Yohay K, Ballon D, Dyke J, Kaminksy SM, Hackett NR, Crystal RG. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther Methods. 2012 Oct;23(5):324-35. doi: 10.1089/hgtb.2012.120. Epub 2012 Nov 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the tolerance of the intracerebral administration of a single dose of AAVrh.10cuARSA Tolerance will be measured by :
Adverse event,
Clinical and neurological exams,
Laboratory tests,
Neuroimagery (CT scan, brain MRI).
During the two years follow-up
Secondary Evaluate the efficacy of intracerebral administration of a single dose of AAVrh.10cuARSA to stop the disease progression. Efficacy will be measured by:
MLD neurological severity score,
Neurological evaluation,
Motor scores (GMFM, Ashworth and ICARS),
Cognitive functions (Bayley Scales of Infant Development (BSID)(0-42 months), or Wechsler Preschool and Primary Scale of Intelligence-III (WPPSI-III) (43 months-6 years)),
MLD severity MRI score, MRI-DTI parameters, measurement of cerebral atrophy and spectroscopy,
Neuroelectrophysiological tests (peripheral nerve conduction velocity, visual, auditory and somatosensory evoked potentials).
During the two years follow-up
See also
  Status Clinical Trial Phase
Completed NCT00383448 - HSCT for High Risk Inherited Inborn Errors Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT01303146 - Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Active, not recruiting NCT04628364 - The Natural History of Metachromatic Leukodystrophy Study (HOME Study)
Enrolling by invitation NCT05368038 - ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Withdrawn NCT00639132 - The Natural History of Metachromatic Leukodystrophy
Completed NCT00683189 - Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy N/A
Recruiting NCT02171104 - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Active, not recruiting NCT03392987 - A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD) Phase 2
Recruiting NCT02559830 - Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Phase 1/Phase 2
Completed NCT00004378 - Stem Cell Transplantation (SCT) for Genetic Diseases N/A
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Active, not recruiting NCT04283227 - OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD) Phase 3
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04925349 - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Active, not recruiting NCT00005900 - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation N/A
Active, not recruiting NCT01560182 - Gene Therapy for Metachromatic Leukodystrophy (MLD) Phase 1/Phase 2
Completed NCT01586455 - Human Placental-Derived Stem Cell Transplantation Phase 1